Lung Cancer (IMAGE) University of Pennsylvania School of Medicine Caption Treating metastatic non-small cell lung cancer (NSCLC) patients with the immunotherapy drug pembrolizumab after they've completed locally ablative therapy almost tripled the median progression-free survival (PFS) compared to the historical average. Credit Penn Medicine Usage Restrictions None License Licensed content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.